Jon Cuthbert - Author on Grafa
Tudo
Telix Pharmaceuticals hits FY25 revenue guidance as Q4 sales surge
Telix Pharmaceuticals (ASX:TLX) reported strong commercial and operational performance for the quarter ended Dec. 31, 2025, achieving its upgraded full-year FY25 revenue guidance with unaudited group revenue of approximately US$804 million.
Corvus stock soars as oral eczema drug hits 75% response rate
Corvus Pharmaceuticals (NASDAQ:CRVS) shares skyrocketed more than 60% in early trading Tuesday after the company reported that its experimental oral therapy significantly cleared skin in patients with moderate-to-severe atopic dermatitis.
MSC Income Fund sees net asset value rise on robust credit performance
MSC Income Fund (NYSE:MAIN) signaled a strong finish to 2025, providing preliminary fourth-quarter results that point to rising asset values and double-digit returns on equity as it navigates a stabilizing interest rate environment.
Japan grants orphan status to Dyne Therapeutics for muscle-wasting drug
Dyne Therapeutics (NASDAQ:DYN) secured a regulatory win in Asia as Japanese authorities granted orphan drug status to its lead candidate for myotonic dystrophy, providing the biotech with a clear path toward market exclusivity in the world’s third-largest pharmaceutical market.







-1-640x358.jpg&w=1200&q=75)


